A Roses

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Pharmacogenetics and drug development: the path to safer and more effective drugs
    Allen D Roses
    Genetics Research, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA
    Nat Rev Genet 5:645-56. 2004
  2. doi request reprint Genome-wide screening for drug discovery and companion diagnostics
    Allen D Roses
    Senior Vice President, Pharmacogenetics, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA
    Expert Opin Drug Discov 2:489-501. 2007
  3. ncbi request reprint "Personalized medicine: elusive dream or imminent reality?": A commentary
    A Roses
    Genetics Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Clin Pharmacol Ther 81:801-5. 2007
  4. ncbi request reprint On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease
    Allen D Roses
    Genetic Research, GlaxoSmithKline Research and Development, Five Moore Drive, 5 5616, Research Triangle Park, NC 27709, USA
    J Alzheimers Dis 9:361-6. 2006
  5. ncbi request reprint Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease)
    A D Roses
    Genetics Research, GlaxoSmithKline Research and Development, NC 27709, USA
    Pharmacogenomics J 7:10-28. 2007
  6. ncbi request reprint Applying technologies towards safe and effective medicines
    Allen D Roses
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Biotechniques 39:563-4. 2005
  7. ncbi request reprint Disease-specific target selection: a critical first step down the right road
    Allen D Roses
    GlaxoSmithKline R and D, Research Triangle Park, NC 27709, USA
    Drug Discov Today 10:177-89. 2005
  8. ncbi request reprint Drug development and Alzheimer disease
    Allen D Roses
    GlaxoSmithKline Research and Development, Genetics Research, Neurology Centre for Excellence in Drug Discovery, Research Triangle Park, NC 27709, USA
    Am J Geriatr Psychiatry 11:123-30. 2003
  9. pmc A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension
    J Chen
    Department of Genomic Sciences, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709 3398, USA
    Genome Res 10:549-57. 2000
  10. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Pharmacogenetics and drug development: the path to safer and more effective drugs
    Allen D Roses
    Genetics Research, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA
    Nat Rev Genet 5:645-56. 2004
    ..The rapid identification of adverse events during and after drug development using genomic mapping tools is also reviewed...
  2. doi request reprint Genome-wide screening for drug discovery and companion diagnostics
    Allen D Roses
    Senior Vice President, Pharmacogenetics, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA
    Expert Opin Drug Discov 2:489-501. 2007
    ..The anticipated successes are effective and safe medicines for unmet medical needs, with a framework for sustaining drug pipelines...
  3. ncbi request reprint "Personalized medicine: elusive dream or imminent reality?": A commentary
    A Roses
    Genetics Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Clin Pharmacol Ther 81:801-5. 2007
    ..One is to simply answer the question as directly and succinctly as possible; another is to expand on the questions. For the purpose of this Commentary, I try to do both...
  4. ncbi request reprint On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease
    Allen D Roses
    Genetic Research, GlaxoSmithKline Research and Development, Five Moore Drive, 5 5616, Research Triangle Park, NC 27709, USA
    J Alzheimers Dis 9:361-6. 2006
    ..Rosiglitazone, a PPARgamma agonist which also leads to mitochondrial proliferation shown efficacy as a monotherapy in a Phase IIB clinical trial of 511 patients in an APOE allele-specific analysis...
  5. ncbi request reprint Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease)
    A D Roses
    Genetics Research, GlaxoSmithKline Research and Development, NC 27709, USA
    Pharmacogenomics J 7:10-28. 2007
    ..Pharmacogenetics is currently being used across the pipeline to prevent attrition and to create safer and more effective medicines...
  6. ncbi request reprint Applying technologies towards safe and effective medicines
    Allen D Roses
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Biotechniques 39:563-4. 2005
  7. ncbi request reprint Disease-specific target selection: a critical first step down the right road
    Allen D Roses
    GlaxoSmithKline R and D, Research Triangle Park, NC 27709, USA
    Drug Discov Today 10:177-89. 2005
    ..This review summarizes the methods and intensive data analyses leading to target gene identification for type 2 diabetes mellitus, including the statistical permutation methodology used to correct for many variables...
  8. ncbi request reprint Drug development and Alzheimer disease
    Allen D Roses
    GlaxoSmithKline Research and Development, Genetics Research, Neurology Centre for Excellence in Drug Discovery, Research Triangle Park, NC 27709, USA
    Am J Geriatr Psychiatry 11:123-30. 2003
  9. pmc A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension
    J Chen
    Department of Genomic Sciences, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709 3398, USA
    Genome Res 10:549-57. 2000
    ..It can be readily adapted to an automated, high-throughput genotyping system. [Primer sequences used in this study are available as online supplementary materials at www.genome.org.]..
  10. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005
    ....
  11. ncbi request reprint On the utility of data from the International HapMap Project for Australian association studies
    Jim Stankovich
    Division of Genetics and Bioinformatics, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, 3050 Parkville, Victoria, Australia
    Hum Genet 119:220-2. 2006
    ..Patterns of LD in the Australian and HapMap samples are similar, and tag SNPs chosen using HapMap genotypes perform almost as well on Australian samples as tags chosen using Australian genotypes...
  12. ncbi request reprint Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
    Seth Hetherington
    HIV Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Lancet 359:1121-2. 2002
    ..Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged...
  13. ncbi request reprint Pharmacogenetics place in modern medical science and practice
    Allen D Roses
    Genetics Research, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Life Sci 70:1471-80. 2002
    ..Pharmacogenetics has the potential of changing the pipeline model of drug discovery, clinical development, and mass customization marketing...
  14. pmc Age at onset in two common neurodegenerative diseases is genetically controlled
    Yi Ju Li
    Department of Medicine, Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Am J Hum Genet 70:985-93. 2002
    ..62. These data suggest that a common gene affects AAO in these two common complex neurodegenerative diseases...
  15. ncbi request reprint Use of whole-genome association scans in disease gene identification, drug discovery and development
    Allen D Roses
    Duke University, R David Thomas Center, 1 Towerview Drive, Suite 343, Box 90120, Durham, NC 27708, USA
    IDrugs 10:797-804. 2007
    ..This feature article discusses the use of whole-genome association scans in disease gene identification, drug discovery and development...
  16. ncbi request reprint Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
    Hao Li
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Arch Neurol 65:45-53. 2008
    ..To identify single-nucleotide polymorphisms (SNPs) associated with risk and age at onset of Alzheimer disease (AD) in a genomewide association study of 469 438 SNPs...
  17. doi request reprint Replication study of the insulin receptor gene in migraine with aura
    Christian Netzer
    Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany
    Genomics 91:503-7. 2008
    ..005. In conclusion, further association studies for rs2860174 with even larger numbers of individuals are required to exclude or confirm definitely a small effect of this SNP on migraine susceptibility...
  18. ncbi request reprint Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways
    John P Cogswell
    Department of Pharmacogenetics, GlaxoSmithKline Inc, Research Triangle Park, NC 27709, USA
    J Alzheimers Dis 14:27-41. 2008
    ..We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease...
  19. pmc The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research
    Matthew R Nelson
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Am J Hum Genet 83:347-58. 2008
    ..The genotype and demographic data from this reference sample are freely available through the NCBI database of Genotypes and Phenotypes (dbGaP)...
  20. doi request reprint Pharmacogenetics in drug discovery and development: a translational perspective
    Allen D Roses
    Deane Drug Discovery Institute, Duke University Medical Center and Fuqua School of Business, Durham, North Carolina 27708, USA
    Nat Rev Drug Discov 7:807-17. 2008
    ....
  21. ncbi request reprint Genome-based pharmacogenetics and the pharmaceutical industry
    Allen D Roses
    GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA
    Nat Rev Drug Discov 1:541-9. 2002
    ....
  22. ncbi request reprint Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations
    Arlene R Hughes
    GlaxoSmithKline, NC 27709, USA
    Pharmacogenomics 5:203-11. 2004
    ..Even after a marker set is identified, appropriate clinical identification and management of hypersensitivity to abacavir must remain the cornerstone of clinical practice...
  23. ncbi request reprint ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory
    Ofir Levi
    The Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel Aviv University, 69978, Ramat Aviv, Israel
    Neurobiol Dis 13:273-82. 2003
    ..This provides a novel mechanism by which environmental factors can modulate the function and phenotypic expression of the apoE genotype...
  24. ncbi request reprint Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease
    Yi Ju Li
    Department of Medicine, Center for Human Genetics, Institute for Genome Science and Policy, Duke University Medical Center, Box 3445, Durham, NC 27710, USA
    Hum Mol Genet 12:3259-67. 2003
    ..This is provocative given reports of the possible role of inflammation in these two neurodegenerative disorders...
  25. ncbi request reprint Pharmacogenetics to predict drug-related adverse events
    David A Hosford
    Department of Genetics Research, GlaxoSmithKline R and D, Research Triangle Park, North Carolina 27709, USA
    Toxicol Pathol 32:9-12. 2004
    ..Together, these studies demonstrate in a stepwise manner the feasibility of using pharmacogenetic approaches to predict DRAEs...
  26. ncbi request reprint Analysis of European mitochondrial haplogroups with Alzheimer disease risk
    Joelle M van der Walt
    Department of Medicine, Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Neurosci Lett 365:28-32. 2004
    ..We suggest that variations within haplogroup U may be involved in AD expression in combination with environmental exposures or nuclear proteins other than APOE...
  27. pmc A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study
    Elizabeth R Hauser
    Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Am J Hum Genet 75:436-47. 2004
    ..These data provide initial areas of the human genome where further investigation may reveal susceptibility genes for early-onset CAD...
  28. ncbi request reprint The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease
    Sofia A Oliveira
    Department of Medicine and Center for Human Genetics, Institute for Genome Sciences and Policy, Box 3445, Duke University Medical Center, Durham, NC 27710, USA
    Neurosci Lett 347:143-6. 2003
    ..We found no evidence of significant association of this polymorphism with risk of AD using family-based and case-control tests of association...
  29. ncbi request reprint SNPs--where's the beef?
    Allen D Roses
    GlaxoSmithKline, Genetics Research, Research Triangle Park, NC 27709, USA
    Pharmacogenomics J 2:277-83. 2002
  30. ncbi request reprint Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease
    Kristin K Nicodemus
    Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurogenetics 5:201-8. 2004
    ..In conclusion, SNPs +5361, or a SNP in strong linkage disequilibrium, may confer some additional risk for developing AD beyond the risk due to APOE-4; however, the effect independent of APOE-4 is likely to be small...
  31. pmc Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22
    William K Scott
    Department of Medicine, Duke University Medical Center, and Center for Human Genetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Am J Hum Genet 73:1041-51. 2003
    ..These results indicate that linkage to chromosome 9p is strongest in late-onset AD and that regions on chromosome 2q34 and 15q22 are linked to early-onset AD and very-late-onset AD, respectively...
  32. doi request reprint Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities
    Allen D Roses
    Duke University Medical Center and the Fuqua School of Business, Durham, NC, USA
    Alzheimers Dement 4:164-6. 2008
  33. ncbi request reprint Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications
    Paul W Norbert
    J Mol Med (Berl) 81:135-40. 2003
    ..Finally, we provide a framework for the analysis of social accountability that can be used for technology development and technology assessment with regard to pharmacogenomics in particular and molecular medicine in general...
  34. pmc Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons
    Jens Brodbeck
    Gladstone Institute of Neurological Disease and Gladstone Institute of Cardiovascular Disease, The J David Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 105:1343-6. 2008
    ..Rosiglitazone rescued this detrimental effect. Thus, rosiglitazone might improve cognition in AD patients by increasing dendritic spine density...
  35. ncbi request reprint A single-nucleotide polymorphism tagging set for human drug metabolism and transport
    Kourosh R Ahmadi
    Department of Biology Galton Lab, University College London, The Darwin Building, Gower Street, London WC1E 6BT, UK
    Nat Genet 37:84-9. 2005
    ..The analyses also suggest that rare variation is not amenable to tagging strategies...
  36. pmc The knockout mouse project
    Christopher P Austin
    National Human Genome Research Institute, National Institutes of Health, Building 31, Room 4B09, 31 Center Drive, Bethesda, Maryland 20892, USA
    Nat Genet 36:921-4. 2004
    ..It is time to harness new technologies and efficiencies of production to mount a high-throughput international effort to produce and phenotype knockouts for all mouse genes, and place these resources into the public domain...
  37. ncbi request reprint Medical applications of haplotype-based SNP maps: learning to walk before we run
    Eric Lai
    Nat Genet 32:353. 2002
  38. ncbi request reprint Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study
    Elizabeth R Hauser
    Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 145:602-13. 2003
    ..Early onset (premature) coronary artery disease (EOCAD) is known to have a particularly strong genetic component. However, the actual genes leading to this increased risk of CAD remain obscure...